Immunological Medicine is an international, peer-reviewed, open access journal publishing high-quality original research in clinical immunology. Immunological Medicine is the Official Journal of the Japanese Society of Clinical Immunology (JSCI).
Recent progress in the field of clinical immunology has been remarkable. Many diseases and conditions, including autoimmune diseases, allergy-related diseases, infectious diseases, malignant diseases, immunodeficiency and transplantation-related conditions are associated with immunological abnormalities and require immunological approaches from various medical fields.
Clinical immunology plays an increasingly important role as the bridge between basic research and clinical practice, with the significance of translational research rapidly increasing in recent years. Considering such developments, the society aims to publish an international and interdisciplinary journal for dissemination to a global audience.
Immunological Medicine focuses on many diseases and conditions associated with immunological abnormalities that require immunological approaches from various medical fields, including:
Autoimmune diseases
Allergy-related diseases
Infectious diseases
Malignant diseases
Immunodeficiency and transplantation-related conditions
Immunological Medicine encourages the submission of original manuscripts covering a wide range of topics such as rheumatology, allergology, oncology, hematology, cardiology, neurology, respiratory medicine, gastroenterology, nephrology, dermatology, pediatrics and other medical topics that relate to both basic and clinical immunology.
Immunological Medicine publishes original articles, review articles, case reports, and rapid communications article types.
All submitted manuscripts, including invited review articles, are subject to single-anonymized peer-review by at least two independent, anonymous referees. To facilitate the peer-review process and subsequent publication of articles, the journal has a Transmitting Editor system in place. Transmitting Editors are responsible for the nomination of reviewers and for making the first decision of ‘accept’, ‘revision required’ or ‘reject’ on submitted manuscripts.
The Editorial Board is responsible for the final decision of ‘accept’ or ‘reject’ on submitted manuscripts, and the subsequent order in which articles are published. All articles are made freely and permanently available online through gold open access publication.
Read the
Journal metrics
Usage
131K annual downloads/views
Citation metrics
2.7 (2023) Impact Factor
Q2 Impact Factor Best Quartile
7.1 (2023) CiteScore (Scopus)
Q2 CiteScore Best Quartile
1.030 (2023) SNIP
1.031 (2023) SJR
Speed/acceptance
27 days avg. from submission to first
decision
38 days avg. from submission to first
post-review decision
9 days avg. from acceptance to online
publication
35% acceptance rate
Understanding and using journal metrics
Journal metrics can be a useful tool for readers, as well as for authors
who are deciding where to submit their next manuscript for publication.
However, any one metric only tells a part of the story of a journal’s
quality and impact. Each metric has its limitations which means that it
should never be considered in isolation, and metrics should be used to
support and not replace qualitative review.
We strongly recommend that you always use a number of metrics, alongside
other qualitative factors such as a journal’s aims & scope, its
readership, and a review of past content published in the journal. In
addition, a single article should always be assessed on its own merits and
never based on the metrics of the journal it was published in.
Usage and acceptance rate data above are for the last full calendar year
and are updated annually in February. Speed data is updated every six
months, based on the prior six months. Citation metrics are updated
annually mid-year. Please note that some journals do not display all of
the following metrics
(find out why).
Usage:
the total number of times articles in the journal were viewed by users
of Taylor & Francis Online in the previous calendar year, rounded to the
nearest thousand.
Citation Metrics
Impact Factor*:
the average number of citations received by articles published in the
journal within a two-year window. Only journals in the Clarivate Science
Citation Index Expanded (SCIE), Social Sciences Citation Index (SSCI),
Arts and Humanities Citation Index (AHCI) and the Emerging Sources
Citation Index (ESCI) have an Impact Factor.
Impact Factor Best Quartile*:
the journal’s highest subject category ranking in the Journal Citation
Reports. Q1 = 25% of journals with the highest Impact Factors.
5 Year Impact Factor*:
the average number of citations received by articles in the journal
within a five-year window.
CiteScore (Scopus)†:
the average number of citations received by articles in the journal over
a four-year period.
CiteScore Best Quartile†:
the journal’s highest CiteScore ranking in a Scopus subject category. Q1
= 25% of journals with the highest CiteScores.
SNIP
(Source Normalized Impact per Paper):
the number of citations per paper in the journal, divided by citation
potential in the field.
SJR
(Scimago Journal Rank):
Average number of (weighted) citations in one year, divided by the
number of articles published in the journal in the previous three years.
Speed/acceptance
From submission to first decision:
the average (median) number of days for a manuscript submitted to the
journal to receive a first decision. Based on manuscripts receiving a
first decision in the last six months.
From submission to first post-review decision:
the average (median) number of days for a manuscript submitted to the
journal to receive a first decision if it is sent out for peer review.
Based on manuscripts receiving a post-review first decision in the last
six months.
From acceptance to online publication:
the average (median) number of days from acceptance of a manuscript to
online publication of the Version of Record. Based on articles published
in the last six months.
Acceptance rate:
articles accepted for publication by the journal in the previous
calendar year as percentage of all papers receiving a final decision.
Dr Tatsuya Atsumi - Department of MedicineⅡ, Hokkaido University Graduate School of Medicine
Associate Editor-in-Chief
Dr Tomohiro Morio - Department of Pediatrics and Developmental Biology, Tokyo Medical and Dental University
Editorial Board
Dr Keishi Fujio - The University of Tokyo Dr Satoshi Hayakawa - Division of Microbiology, Department of Pathlogy and Microbiology, Nihon University School of Medicine Dr Tadakazu Hisamatsu - The Third Department of Internal Medicine, Kyorin University School of Medicine Dr Hideto Kameda - Division of Rheumatology, Toho University Ohashi Medical Center Dr Masataka Kuwana - Department of Allergy and Rheumatology, Nippon Medical School Graduate School of Medicine Dr Isao Matsumoto - Department of Internal Medicine, Faculty of Medicine, University of Tsukuba Dr Sachiko Miyake - Department of Immunology, Juntendo University School of Medicine Dr Toshihiko Torigoe - Sapporo Medical University School of Medicine
Abstracting and indexing
Immunological Medicine is included in the following Abstracting and Indexing services: PubMed Scopus Directory of Open Access Journals (DOAJ)
Open access
Immunological Medicine is an open access journal and only publishes open access articles. Publishing open access means that your article will be free to access online immediately on publication, increasing the visibility, readership, and impact of your research.
Why choose open access?
Increase the discoverability and readership of your article
Make an impact and reach new readers, not just those with easy access to a research library
Freely share your work with anyone, anywhere
Comply with funding mandates and meet the requirements of your institution, employer or funder
Rigorous peer review for every open access article
Article Publishing Charges (APC)
To publish open access in this journal you may be asked to pay an Article Publishing Charge (APC). You may be able to publish your article at no cost to yourself or with a reduced APC if your institution or research funder has an open access agreement or membership with Taylor & Francis. Discounts and waivers may also be available for researchers in selected countries when publishing in open access journals.
Japanese Society of Clinical Immunology and our publisher Taylor & Francis make every effort to ensure the accuracy of all the information (the "Content") contained in our publications. However, Japanese Society of Clinical Immunology and our publisher Taylor & Francis, our agents (including the editor, any member of the editorial team or editorial board, and any guest editors), and our licensors make no representations or warranties whatsoever as to the accuracy, completeness, or suitability for any purpose of the Content. Any opinions and views expressed in this publication are the opinions and views of the authors, and are not the views of or endorsed by Japanese Society of Clinical Immunology and our publisher Taylor & Francis. The accuracy of the Content should not be relied upon and should be independently verified with primary sources of information. Japanese Society of Clinical Immunology and our publisher Taylor & Francis shall not be liable for any losses, actions, claims, proceedings, demands, costs, expenses, damages, and other liabilities whatsoever or howsoever caused arising directly or indirectly in connection with, in relation to, or arising out of the use of the Content. Terms & Conditions of access and use can be found at http://www.tandfonline.com/page/terms-and-conditions .
Ready to submit?
Start a new submission or continue a submission in progress
![Sample our Medicine, Dentistry, Nursing & Allied Health journals, sign in here to start your FREE access for 14 days]({"type":"image" , "src" : "/sda/110817/Subject-Sample-2021-Medicine-Dentistry-Nursing-Allied-Health.jpg"})